River Vision Development Corp.

Horizon Therapeutics PLC may have been forced to conduct a larger postmarket study than expected for its newly approved Tepezza following advisory committee concerns the proposed size was not suffici

Several seemingly minor safety issues could complicate the labeling discussions for Horizon Therapeutics PLC 's teprotumumab, proposed for active thyroid eye disease (TED), a rare condition. US Food

Horizon Therapeutics PLC 's teprotumumab cruised to a favorable advisory committee recommendation for use in active thyroid eye disease (TED), with a recognition that some safety issues should be clar

Horizon Therapeutics PLC is building out its commercial plans for the launch of teprotumumab for the rare autoimmune condition thyroid eye disease (TED) in early 2020. Teprotumumab is pending at the